throbber
Lacosamide (Vimpat®) | UCB
`
`Page 1 of 11
`
`[] [/search]
`
`Clinical Study Information - Vimpat® (lacosamide)
`
`Back to the overview page [/rd/clinical-study-information]
`
`Abbreviated title Phase Study ID Registry database
`
`Study results
`
`Study
`summary
`
`P
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`B 2
`
`0
`
`Phase EP0008
`
`NCT01710657
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT01710657?
`term=NCT01710657&rank=1]
`
`Phase EP0009
`
`3
`Ongoing
`
`NCT01832038
`[https://clinicaltrials.gov/ct2/show/study/NCT01832038?
`term=NCT01832038&rank=1]
`
`A Study to
`Evaluate the
`Efficacy and
`Safety of
`Adjunctive
`Therapy With
`Lacosamide in
`Adults With
`Partial Onset
`Seizures
`
`Study to Evaluate
`the Safety,
`Tolerability, and
`Efficacy of Long-
`term Adjunctive
`Therapy With
`Lacosamide in
`Adults With
`Partial-onset
`Seizures
`
`NCT02192814
`[https://clinicaltrials.gov/ct2/show/study/NCT02192814?
`term=NCT02192814&rank=1]
`
`NCT01964560
`[https://clinicaltrials.gov/ct2/show/study/NCT01964560?
`term=NCT01964560&rank=1]
`2012-005012-26
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2012-005012-26]
`
`NCT02124564
`[https://clinicaltrials.gov/ct2/show/study/NCT02124564?
`term=NCT02124564&rank=1]
`
`Phase EP0024
`
`Open-label Study
`3
`Ongoing
`to Evaluate the
`Safety and
`Tolerability of iv
`Lacosamide in
`Japanese Adults
`With Partial-onset
`Seizures
`
`Phase EP0034
`
`3
`Ongoing
`
`Long-term
`Extension Study
`to Investigate
`Lacosamide as an
`Add-on Therapy
`in Children With
`Partial Onset
`Seizures
`
`Phase EP0057
`
`A Trial to Evaluate
`3
`Ongoing
`the Long Term
`Safety and
`Tolerability of
`Lacosamide
`Taken as
`Monotherapy in
`Adults With
`Partial-onset
`Seizures
`
`Phase SP0615
`
`NCT00552305
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00552305?
`term=NCT00552305&rank=1]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00552305?
`term=NCT00552305&rank=1]
`
`To Determine
`Tolerability and
`Efficacy of Long-
`term Oral
`Lacosamide in
`Patients With
`Partial Seizures
`
`Phase SP0616
`
`NCT00800215
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00800215?
`term=NCT00800215&rank=1]
`
`A Trial to
`Investigate the
`Safety,
`Tolerability and
`Pharmacokinetics
`of Intravenous
`SPM 927 (n/a)
`
`PDF
`
`Disease area
`studied
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`ARGENTUM Exhibit 1186
`Argentum Pharmaceuticals LLC v. Research Corporation Technologies, Inc.
`IPR2016-00204
`
`00001
`
`

`
`Lacosamide (Vimpat®) | UCB
`
`Disease area
`studied
`
`Neuropathic
`Pain
`
`Page 2 of 11
`
`Study
`summary
`
`P
`
`M N P
`
`a
`
`Sh
`Pa
`
`W 2
`
`0
`
`Zi
`C
`
`G N 1
`
`)
`11
`Fe
`
`N (
`
`E 2
`
`0
`
`B P
`
`a
`S4
`Sc
`
`A (
`
`A A H N 3
`
`2
`of
`Fe
`
`Abbreviated title Phase Study ID Registry database
`
`Study results
`
`Phase SP0647
`
`NCT00237458
`An Open-label
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00237458?
`Continuation
`term=NCT00237458&rank=1]
`Trial to Assess the
`Continued
`Efficacy and
`Safety of
`Ascending Doses
`of Lacosamide in
`Subjects With
`Chronic
`Refractory
`Neuropathic Pain
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00237458?
`term=NCT00237458&rank=1]
`
`Phase SP0665
`
`NCT00861042
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/NCT00861042?
`term=NCT00861042&rank=1]
`
`Phase SP0690
`
`NCT00238511
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00238511?
`term=NCT00238511&rank=1]
`
`PDF
`
`Phase SP0742
`
`NCT00235469
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00235469?
`term=NCT00235469&rank=1]
`
`PDF
`
`Phase SP0743
`
`NCT00238524
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00238524?
`term=NCT00238524&rank=1]
`
`PDF
`
`Neuropathic
`Pain
`
`Postherpetic
`Neuralgia
`
`Neuropathic
`Pain
`
`Neuropathic
`Pain
`
`An Open-label
`follow-on Trial to
`Assess the Long-
`term Safety and
`Efficacy of Oral
`SPM 927 in
`Subjects With
`Diabetic
`Neuropathy
`
`An Open-Label
`Follow-on Trial
`to Assess the
`Long-Term
`Safety and
`Efficacy of Oral
`SPM 927 in
`Subjects With
`Postherpetic
`Neuralgia (PHN)
`
`A Trial to Assess
`the Efficacy and
`Safety of SPM
`927 in Subjects
`With Painful
`Distal Diabetic
`Neuropathy
`
`A Trial to Assess
`the Efficacy and
`Safety of SPM
`927 (Lacosamide)
`in Subjects With
`Painful Distal
`Diabetic
`Neuropathy
`
`Neuropathic
`Pain
`
`Phase SP0745
`
`NCT00235443
`A Follow-On Trial
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00235443?
`to Assess the
`term=NCT00235443&rank=1]
`Long Term Safety
`and Efficacy of
`SPM 927 in
`Painful Distal
`Diabetic
`Neuropathy
`
`Neuropathic
`Pain
`
`Study Evaluating
`Long-term Safety
`and Efficacy of
`Lacosamide in
`Subjects With
`Painful Distal
`Diabetic
`Neuropathy.
`
`Phase SP0746
`
`NCT00546351
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00546351?
`term=NCT00546351&rank=1]
`2004-000551-42
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2004-000551-42]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00235443?
`term=NCT00235443&rank=1]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00546351?
`term=NCT00546351&rank=1]
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`N (
`
`E 2
`
`0
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`00002
`
`

`
`Lacosamide (Vimpat®) | UCB
`
`Page 3 of 11
`
`Study
`summary
`
`P
`
`C 2
`
`0
`
`PDF
`
`H 2
`
`0
`
`PDF
`
`H 2
`
`0
`
`Kr
`20
`
`Sh
`20
`
`Si
`Pa
`S1
`
`C E
`
`u
`IA
`Se
`20
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`Disease area
`studied
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Abbreviated title Phase Study ID Registry database
`
`Study results
`
`Phase SP0754
`
`NCT00136019
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00136019?
`term=NCT00136019&rank=1]
`
`PDF
`
`Phase SP0755
`
`NCT00220415
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00220415?
`term=NCT00220415&rank=1]
`
`PDF
`
`Phase SP0756
`
`NCT00522275
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00522275?
`term=NCT00522275&rank=1]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00522275?
`term=NCT00522275&rank=1]
`
`Phase SP0757
`
`NCT00151879
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00151879?
`term=NCT00151879&rank=1]
`2004-002322-22
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2004-002322-22]
`
`PDF
`
`SPM 927
`(400mg/Day and
`600mg/Day) as
`Adjunctive
`Therapy in
`Subjects With
`Partial Seizures
`With or Without
`Secondary
`Generalization
`
`A Multicenter,
`Double-blind,
`Randomized,
`Placebo-
`controlled,
`Parallel Group
`Trial to
`Investigate the
`Efficacy and
`Safety of SPM
`927 (200mg/Day
`and 400mg/Day)
`as Adjunctive
`Therapy in
`Subjects With
`Partial Seizures
`With or Without
`Secondary
`Generalization
`
`Determine Safety
`and Efficacy of
`Long-term Oral
`Lacosamide in
`Patients With
`Partial Seizures
`
`Safety and
`Tolerability of
`Intravenous SPM
`927 as
`Replacement for
`Oral SPM 927 in
`Subjects With
`Partial Seizures
`
`Neuropathic
`Pain
`
`Trial to Assess the
`Phase SP0768
`
`NCT00135109
`Efficacy and
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00135109?
`Safety of SPM
`term=NCT00135109&rank=1]
`927 (200, 400,
`and 600mg/Day)
`in Subjects With
`Painful Distal
`Diabetic
`Neuropathy
`
`PDF
`
`Epilepsy
`
`Assess Safety and
`Efficacy of
`Lacosamide in
`Patients With
`Partial Seizures
`
`Phase SP0774
`
`NCT00515619
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00515619?
`term=NCT00515619&rank=1]
`2004-000152-16
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2004-000152-16]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00515619?
`term=NCT00515619&rank=1]
`
`Neuropathic
`Pain
`
`A Trial to Assess
`the Long-term
`Safety and
`Efficacy of
`Lacosamide in
`Subjects With
`Painful Diabetic
`Neuropathy
`
`Phase SP0830
`
`NCT00220337
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00220337?
`term=NCT00220337&rank=1]
`2004-000960-28
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2004-000960-28]
`
`PDF
`
`Epilepsy
`
`A Multicenter,
`Open-Label
`Study To
`Investigate The
`
`Phase SP0847
`
`NCT00938431
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00938431?
`term=NCT00938431&rank=1]
`2011-001558-27
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`00003
`
`

`
`Lacosamide (Vimpat®) | UCB
`
`Page 4 of 11
`
`Study
`summary
`
`P
`
`[]
`
`[]
`
`Bo
`
`N S
`
`2 M N (
`
`A 2
`
`0
`
`Disease area
`studied
`
`Epilepsy
`
`Neuropathic
`Pain
`
`Abbreviated title Phase Study ID Registry database
`
`Study results
`
`Safety And
`Pharmacokinetics
`Of Lacosamide In
`Children With
`Partial Seizures
`
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2011-001558-27]
`
`Phase SP0848
`
`2
`Ongoing
`
`NCT00938912
`[https://clinicaltrials.gov/ct2/show/study/NCT00938912?
`term=NCT00938912&rank=1]
`2011-001559-35
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2011-001559-35]
`
`Phase SP0874
`
`NCT00350103
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00350103?
`term=NCT00350103&rank=1]
`2005-005788-27
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2005-005788-27]
`
`PDF
`
`An Open-Label
`Study to
`Determine
`Safety ,
`Tolerability, and
`Efficacy of Oral
`Lacosamide in
`Children With
`Epilepsy
`
`A Trial to Assess
`the Efficacy and
`Safety of
`400mg/Day
`Lacosamide in
`Subjects With
`Painful Diabetic
`Neuropathy
`
`D C 1
`
`: 6
`
`4
`th
`So
`3-
`U
`
`W E
`
`p
`–
`
`D C 1
`
`: 6
`
`4
`th
`So
`3-
`U
`
`D C 1
`
`: 6
`
`4
`th
`So
`3-
`U
`
`Phase SP0887
`
`NCT00401830
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00401830?
`term=NCT00401830&rank=1]
`
`Fibromyalgia Assessing
`Efficacy and
`Safety of
`Lacosamide
`Compared to
`Placebo in
`Reducing Signs
`and Symptoms of
`Fibromyalgia
`Syndrome.
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00401830?
`term=NCT00401830&rank=1]
`
`Phase SP0902
`
`NCT00520741
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00520741?
`term=NCT00520741&rank=1]
`2007-005439-27
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2007-005439-27]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00520741?
`term=NCT00520741&rank=1]
`
`Phase SP0904
`
`3
`Ongoing
`
`NCT00530855
`[https://clinicaltrials.gov/ct2/show/study/NCT00530855?
`term=NCT00530855&rank=1]
`2007-005440-25
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2007-005440-25]
`
`Epilepsy
`
`Epilepsy
`
`Trial to
`Demonstrate the
`Efficacy and
`Safety of
`Conversion to
`Lacosamide
`Monotherapy for
`Partial-onset
`Seizures (ALEX-
`MT)
`
`Trial to Assess
`Long-term
`Lacosamide
`(LCM)
`Monotherapy
`Use and Safety of
`LCM
`Monotherapy
`and Adjunctive
`Therapy for
`Partial-onset
`Seizures
`
`Osteoarthritis Trial to Assess
`Efficacy and
`Safety of
`Lacosamide in
`Subjects With
`Osteoarthritis of
`the Knee
`
`Phase SP0905
`
`NCT00485472
`2
`
`Terminated [https://clinicaltrials.gov/ct2/show/study/NCT00485472?
`term=NCT00485472&rank=1]
`2006-005048-97
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2006-005048-97]
`
`Migraine
`disorders
`
`SP0906
`NCT00440518
`Phase
`A Study Designed
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00440518?
`to Test the
`term=NCT00440518&rank=1]
`Effectiveness and
`Safety of Treating
`Patients With
`Lacosamide for
`Migraine
`Prophylaxis
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00485472?
`term=NCT00485472&rank=1]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00440518?
`term=NCT00440518&rank=1]
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`00004
`
`

`
`Lacosamide (Vimpat®) | UCB
`
`Abbreviated title Phase Study ID Registry database
`
`Study results
`
`Page 5 of 11
`
`Study
`summary
`
`P
`
`Disease area
`studied
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Fo
`20
`
`Le
`20
`In
`
`C 2
`
`8
`20
`
`W C 6
`
`6
`th
`So
`30
`20
`
`Ya
`
`C 2
`
`1
`of
`So
`6-
`U
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`Phase SP0925
`
`NCT00655551
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00655551?
`term=NCT00655551&rank=1]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00655551?
`term=NCT00655551&rank=1]
`
`Phase SP0926
`
`NCT00655486
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00655486?
`term=NCT00655486&rank=1]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00655486?
`term=NCT00655486&rank=1]
`
`Phase SP0954
`
`NCT00955357
`4
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT00955357?
`term=NCT00955357&rank=1]
`2009-011181-28
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2009-011181-28]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT00955357?
`term=NCT00955357&rank=1]
`
`Phase SP0961
`
`NCT01118949
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT01118949?
`term=NCT01118949&rank=1]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT01118949?
`term=NCT01118949&rank=1]
`
`Phase SP0962
`
`NCT01118962
`2
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT01118962?
`term=NCT01118962&rank=1]
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT01118962?
`term=NCT01118962&rank=1]
`
`Phase SP0966
`
`3
`Ongoing
`
`NCT01969851
`[https://clinicaltrials.gov/ct2/show/study/NCT01969851?
`term=NCT01969851&rank=1]
`2012-001446-18
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2012-001446-18]
`
`Safety of
`Intravenous
`Lacosamide
`Dose Followed
`by Twice Daily
`Oral Lacosamide
`in Subjects With
`Partial-onset
`Seizures
`
`Study to Assess
`the Long-term
`Safety of Oral
`Lacosamide in
`Subjects With
`Partial-onset
`Seizures
`
`Trial to Assess
`Lacosamide as
`the First add-on
`Anti-epileptic
`Drug Treatment
`in Patients With
`Partial-onset
`Seizures
`
`Open-Label
`Study to Assess
`Lacosamide
`Safety as Add-on
`Therapy for
`Primary
`Generalized
`Tonic-Clonic
`Seizures in
`Subjects With
`Epilepsy
`
`Open-Label
`Extension Study
`to Assess the
`Safety and
`Seizure
`Frequency
`Associated With
`Lacosamide for
`Primary
`Generalized
`Tonic-Clonic
`Seizures in
`Subjects With
`Idiopathic
`Generalized
`Epilepsy
`
`A Study to
`Investigate the
`Safety and
`Efficacy of
`Lacosamide
`Added to the
`Patients Current
`Therapy in
`Patients Aged 1
`Month to less
`than 18 Years Old
`With Epilepsy
`Syndromes
`Associated With
`Generalized
`Seizures.
`
`Epilepsy
`
`Study to
`Investigate
`Lacosamide as
`
`Phase SP0969
`
`3
`Ongoing
`
`NCT01921205
`[https://clinicaltrials.gov/ct2/show/study/NCT01921205?
`term=NCT01921205&rank=1]
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`00005
`
`

`
`Lacosamide (Vimpat®) | UCB
`
`Page 6 of 11
`
`Disease area
`studied
`
`Abbreviated title Phase Study ID Registry database
`
`Study results
`
`Study
`summary
`
`P
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Epilepsy
`
`Add-on Therapy
`in Subjects ≥4
`Years to ˂17
`Years of Age With
`Partial Onset
`Seizures
`
`2012-004996-38
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2012-004996-38]
`
`Hormonal and
`Lipid Levels in
`Male Subjects
`After a Switch
`From
`Carbamazepine
`to Lacosamide
`(VICTOR)
`
`eValuation of the
`Efficacy and
`toleRability of
`Vimpat When
`Added to
`lEvetiracetam
`(VERVE)
`
`Phase SP0978
`
`NCT01375374
`3
`
`Terminated [https://clinicaltrials.gov/ct2/show/study/NCT01375374?
`term=NCT01375374&rank=1]
`2010-022534-84
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2010-022534-84]
`
`Phase SP0980
`
`NCT01484977
`3
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT01484977?
`term=NCT01484977&rank=1]
`2011-002461-37
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2011-002461-37]
`
`NCT01243177
`[https://clinicaltrials.gov/ct2/show/study/NCT01243177?
`term=NCT01243177&rank=1]
`2010-019765-28
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2010-019765-28]
`
`NCT01465997
`[https://clinicaltrials.gov/ct2/show/study/NCT01465997?
`term=NCT01465997&rank=1]
`2010-021238-74
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2010-021238-74]
`
`Phase
`SP0993
`3
`Ongoing
`
`Trial Comparing
`the Efficacy and
`Safety of
`Lacosamide
`(LCM) to
`Carbamazepine
`Controlled-
`Release (CBZ-
`CR); Initial
`Monotherapy in
`Epilepsy; Subjects
`Aged 16 and
`Older (SP0993)
`
`Phase SP0994
`
`3
`Ongoing
`
`Evaluating Long
`Term Safety of
`Lacosamide
`(LCM) to
`Carbamazepine
`Controlled-
`release (CBZ-CR);
`Initial
`Monotherapy in
`Epilepsy Subjects
`16 Years and
`Older
`
`Phase SP1007
`
`NCT01235403
`4
`
`Completed [https://clinicaltrials.gov/ct2/show/study/NCT01235403?
`term=NCT01235403&rank=1]
`2010-019268-35
`[https://www.clinicaltrialsregister.eu/ctr-search/search?
`query=2010-019268-35]
`
`Trial to Assess
`Optimized
`Dosage of
`Lacosamide as
`add-on Therapy
`in Patients With
`Partial Onset
`Seizure (SELF)
`
`LINK
`[https://clinicaltrials.gov/ct2/show/results/NCT01235403?
`term=NCT01235403&rank=1]
`
`[]
`
`[]
`
`[]
`
`[]
`
`[]
`
`© 2007 - 2015 UCB S.A., Belgium. All rights reserved
`
`Search
`
`Submit
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`00006
`
`

`
`Lacosamide (Vimpat®) | UCB
`
`Page 7 of 11
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`00007
`
`

`
`Lacosamide (Vimpat®) | UCB
`
`Page 8 of 11
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`00008
`
`

`
`Lacosamide (Vimpat®) | UCB
`
`Page 9 of 11
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`00009
`
`

`
`Lacosamide (Vimpat®) | UCB
`
`Page 10 of 11
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`00010
`
`

`
`Lacosamide (Vimpat®) | UCB
`
`Page 11 of 11
`
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide
`
`6/8/2015
`
`00011

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket